Related Experiment Video
Updated: Oct 27, 2025
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
4.9K
Liver microphysiological platforms for drug metabolism applications
Gulsim Kulsharova1, Akbota Kurmangaliyeva2
1School of Engineering and Digital Sciences, Nazarbayev University, Nur-Sultan, Kazakhstan.
Cell Proliferation
|July 22, 2021
Summary
Liver-on-a-chip platforms offer a promising alternative to animal testing in drug development. These microphysiological systems improve the prediction of drug metabolism and toxicity, potentially reducing costs and timelines.
Area of Science:
- Biotechnology
- Pharmacology
- Toxicology
Background:
- Drug development is expensive, time-consuming, and has low success rates.
- Early identification of toxic compounds is crucial for improving drug development efficiency.
- Drug metabolism, primarily occurring in the liver, significantly impacts drug efficacy and side effects.
Purpose of the Study:
- To review liver microphysiological platforms for drug metabolism studies.
- To highlight the potential of liver-on-a-chip systems in reducing animal testing.
- To discuss the state-of-the-art in vitro platforms for drug metabolism mimicry.
Main Methods:
- Review of current literature on liver-on-a-chip platforms.
- Analysis of stand-alone and multi-organ systems for drug metabolism.
- Evaluation of platforms for recapitulating human liver cell environments.
Main Results:
- Liver-on-a-chip platforms can better mimic the in vivo liver environment.
- These systems show potential in predicting drug response and toxicity in vitro.
- Recent advancements have led to more robust and reproducible platforms.
Conclusions:
- Liver-on-a-chip technology offers a viable alternative to traditional drug testing methods.
- These platforms can enhance the efficiency of drug development by enabling early toxicity screening.
- Further development of microphysiological systems promises to reduce drug development costs and timelines.
Keywords:
drug developmentdrug metabolismliver-on-a-chipmicrofluidicsmicrophysiological platformsmulti-organ chipsMore Related Videos
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
38
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
38
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
37
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
37
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
122
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
122
01:16Drug Biotransformation: Overview
3.2K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
3.2K
01:28Drug Biotransformation: Overview
1.9K
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
1.9K
01:20Measurement of Bioavailability: Pharmacodynamic Methods
37
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
37